Ledger.Open graph →
SEC Form D · filed February 7, 2023

Inhibikase Therapeutics, Inc

Offering
$4.2M
Sold
$4.2M
Exemption
Rule 506(b)
Industry
Pharmaceuticals
Location
Atlanta, GA
Type
—

Rule 506(b): private placement to accredited investors, no public advertising.

People & firms on this filing (12)

Paul Grint, M.D · Atlanta, GADirectorPaul Grint, M.D · Atlanta, GADirectorRoy Freeman M.D · Atlanta, GADirectorRoy Freeman M.D · Atlanta, GADirectorJoseph Frattaroli, C.P.A · Atlanta, GAExecMilton H. Werner Ph.D · Atlanta, GAExec · DirectorJoseph Frattaroli, C.P.A · Atlanta, GAExecMilton H. Werner Ph.D · Atlanta, GAExec · DirectorDennis Berman · Atlanta, GADirectorDennis Berman · Atlanta, GADirectorGisele Dion · Atlanta, GADirectorGisele Dion · Atlanta, GADirector

Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗